Literature DB >> 11760567

Comorbidity considerations in geriatric oncology research.

J W Yates1.   

Abstract

Although it is generally acknowledged that comorbidity has a significant impact on treatment selection and outcomes for elderly patients with cancer, an understanding of how comorbid conditions should influence clinical decisions is quite incomplete. This issue remains an important and challenging area of geriatric oncology research. Measures of comorbidity require recognition, documentation, and accurate data extraction. Extensive prospective evaluations and medical chart reviews have the greatest reliability but are costly. Administrative data are convenient and applicable to large populations, but suffer from relatively poor reliability and therefore should be used with caution. Perhaps in the future more refined nosology and better information systems will improve our understanding and ability to use administrative data sets to study comorbidity in the elderly--the eventual goal of such investigation being evidence-based criteria for care of elderly cancer patients.

Entities:  

Mesh:

Year:  2001        PMID: 11760567     DOI: 10.3322/canjclin.51.6.329

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  10 in total

1.  [The significance of comorbidity and age in radical prostatectomy].

Authors:  M Wirth; M Fröhner
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

2.  Patterns and predictors of home health and hospice use by older adults with cancer.

Authors:  Julie L Locher; Meredith L Kilgore; Michael A Morrisey; Christine S Ritchie
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

3.  TREATMENT AND SURVIVAL PATTERNS IN RELATION TO MULTIMORBIDITY IN PATIENTS WITH LOCOREGIONAL BREAST AND COLORECTAL CANCER.

Authors:  Siran M Koroukian; Paul M Bakaki; Mark D Schluchter; Cynthia Owusu
Journal:  J Geriatr Oncol       Date:  2011-07       Impact factor: 3.599

4.  Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients.

Authors:  Johnny M Hoang; Navneet Upadhyay; Dozie N Dike; Jaekyu Lee; Michael L Johnson; Charles S Cleeland; Tito Mendoza; Hua Chen; Meghana V Trivedi
Journal:  Support Care Cancer       Date:  2019-07-23       Impact factor: 3.603

5.  Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.

Authors:  K Clifton; Yi Min; J Kimmel; J Litton; D Tripathy; M Karuturi
Journal:  Breast Cancer Res Treat       Date:  2019-03-05       Impact factor: 4.872

6.  Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer.

Authors:  Robert B Hines; Chakrapani Chatla; Harvey L Bumpers; John W Waterbor; Gerald McGwin; Ellen Funkhouser; Christopher S Coffey; James Posey; Upender Manne
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

7.  Predictors of patterns of pain, fatigue, and insomnia during the first year after a cancer diagnosis in the elderly.

Authors:  Sharon L Kozachik; Karen Bandeen-Roche
Journal:  Cancer Nurs       Date:  2008 Sep-Oct       Impact factor: 2.592

8.  Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.

Authors:  Mya S Thein; William B Ershler; Ahmedin Jemal; Jerome W Yates; Maria R Baer
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

9.  From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience.

Authors:  Sophie Espenel; Max-Adrien Garcia; Jane-Chloé Trone; Elodie Guillaume; Annabelle Harris; Amel Rehailia-Blanchard; Ming Yuan He; Sarra Ouni; Alexis Vallard; Chloé Rancoule; Majed Ben Mrad; Céline Chauleur; Guy De Laroche; Jean-Baptiste Guy; Pablo Moreno-Acosta; Nicolas Magné
Journal:  Radiat Oncol       Date:  2018-02-02       Impact factor: 3.481

10.  Prognostic Value of Comorbidity for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.

Authors:  Hung-Lung Ke; Ching-Chia Li; Hsiang-Ying Lee; Hung-Pin Tu; Yu-Ching Wei; Hsin-Chih Yeh; Wen-Jeng Wu; Wei-Ming Li
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.